Nothing Special   »   [go: up one dir, main page]

HK1222128A1 - 用於製備氣霧劑的方法和組合物 - Google Patents

用於製備氣霧劑的方法和組合物

Info

Publication number
HK1222128A1
HK1222128A1 HK16110367.6A HK16110367A HK1222128A1 HK 1222128 A1 HK1222128 A1 HK 1222128A1 HK 16110367 A HK16110367 A HK 16110367A HK 1222128 A1 HK1222128 A1 HK 1222128A1
Authority
HK
Hong Kong
Prior art keywords
aerosols
compositions
preparation
methods
Prior art date
Application number
HK16110367.6A
Other languages
English (en)
Inventor
埃里克‧德普拉
毛羅‧塞爾吉
彼得‧卡斯特爾
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of HK1222128A1 publication Critical patent/HK1222128A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16110367.6A 2010-02-11 2016-08-31 用於製備氣霧劑的方法和組合物 HK1222128A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30344710P 2010-02-11 2010-02-11
US201061426610P 2010-12-23 2010-12-23

Publications (1)

Publication Number Publication Date
HK1222128A1 true HK1222128A1 (zh) 2017-06-23

Family

ID=43899571

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110367.6A HK1222128A1 (zh) 2010-02-11 2016-08-31 用於製備氣霧劑的方法和組合物

Country Status (17)

Country Link
US (3) US9713589B2 (zh)
EP (2) EP3501499B1 (zh)
JP (3) JP5951508B2 (zh)
CN (2) CN105380904A (zh)
AU (1) AU2011214299B2 (zh)
CA (1) CA2787718C (zh)
CY (1) CY1122634T1 (zh)
DK (1) DK2533761T3 (zh)
ES (2) ES2738114T3 (zh)
HK (1) HK1222128A1 (zh)
HR (1) HRP20191071T1 (zh)
HU (1) HUE044292T2 (zh)
LT (1) LT2533761T (zh)
PL (2) PL3501499T3 (zh)
PT (2) PT2533761T (zh)
SI (1) SI2533761T1 (zh)
WO (1) WO2011098552A2 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010289417B2 (en) 2009-09-02 2015-08-13 Synedgen, Inc. Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
AU2011214299B2 (en) 2010-02-11 2014-07-31 Ablynx Nv Methods and compositions for the preparation of aerosols
AU2011224207B2 (en) 2010-03-12 2015-11-19 Berg Llc Intravenous formulations of Coenzyme Q10 (CoQ10) and methods of use thereof
PE20140628A1 (es) * 2011-06-17 2014-05-30 Berg Llc Composiciones farmaceuticas inhalables
EP2897587A1 (en) * 2012-09-18 2015-07-29 Adocia Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
DK2970383T3 (da) 2013-03-15 2021-07-05 Univ Texas Fremgangsmåde til behandling af fibrose
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
AU2015239145B2 (en) * 2014-04-03 2019-07-11 Csl Behring Ag Nebulization of immunoglobulin
WO2016040899A1 (en) * 2014-09-11 2016-03-17 Synedgen, Inc. Compositions and methods of use thereof
WO2016055656A1 (en) * 2014-10-10 2016-04-14 Ablynx N.V. Methods of treating rsv infections
EP3204095B8 (en) * 2014-10-10 2019-07-10 Ablynx N.V. Inhalation device for use in aerosol therapy of respiratory diseases
KR102698051B1 (ko) * 2015-02-27 2024-08-26 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 폴리펩타이드 치료제 및 이의 용도
EP3452505A1 (en) 2016-05-02 2019-03-13 Ablynx NV Treatment of rsv infection
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
EP4272822A3 (en) 2017-06-02 2024-03-27 Merck Patent GmbH Adamts binding immunoglobulins
WO2020055812A1 (en) 2018-09-10 2020-03-19 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US5938117A (en) 1991-04-24 1999-08-17 Aerogen, Inc. Methods and apparatus for dispensing liquids as an atomized spray
DE69330523D1 (de) 1992-08-21 2001-09-06 Vrije Universiteit Brussel Bru Immunoglobuline ohne leichte ketten
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US5586550A (en) 1995-08-31 1996-12-24 Fluid Propulsion Technologies, Inc. Apparatus and methods for the delivery of therapeutic liquids to the respiratory system
US6014970A (en) 1998-06-11 2000-01-18 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
US5758637A (en) 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US6205999B1 (en) 1995-04-05 2001-03-27 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
US6085740A (en) 1996-02-21 2000-07-11 Aerogen, Inc. Liquid dispensing apparatus and methods
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK0937140T3 (da) 1996-06-27 2008-01-28 Vlaams Interuniv Inst Biotech Antistofmolekyler, som interagerer specifikt med et målmolekyles aktive sted eller klöft
US6670453B2 (en) 1997-10-27 2003-12-30 Unilever Patent Holdings B.V. Multivalent antigen-binding proteins
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
AU3041100A (en) 1999-01-05 2000-07-24 Unilever Plc Binding of antibody fragments to solid supports
DE60013767T3 (de) 1999-01-19 2009-07-09 Unilever N.V. Verfahren zur herstellung von antikörperfragmenten
CN1252264C (zh) 1999-04-22 2006-04-19 荷兰联合利华有限公司 利用单价抗原－结合蛋白抑制病毒感染
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
AU1859201A (en) 1999-11-29 2001-06-12 Unilever Plc Immobilisation of proteins
ES2331051T3 (es) 1999-11-29 2009-12-21 Bac Ip B.V. Inmovilizacion de moleculas de union de antigenos de un dominio.
DE60138333D1 (de) 2000-03-14 2009-05-28 Unilever Nv Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
AU2002229639A1 (en) 2000-12-13 2002-06-24 De Haard, Johannes Joseph Wilhelmus Camelidae antibody arrays
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
US20050037358A1 (en) 2001-12-21 2005-02-17 Serge Muyldermans Method for cloning of variable domain sequences
EP1461085A2 (en) 2002-01-03 2004-09-29 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunoconjugates useful for treatment of tumours
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
EP2267032A3 (en) 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
EP1900753B1 (en) 2002-11-08 2017-08-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
EP1656128A4 (en) 2003-08-12 2007-02-28 William M Yarbrough SINGLE ACNE TREATMENT AND METHOD OF USE
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
KR20070084170A (ko) 2004-10-13 2007-08-24 아블린쓰 엔.브이. 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
EP1844073A1 (en) 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
EP3243839A1 (en) 2005-05-20 2017-11-15 Ablynx N.V. Improved nanobodies tm for the treatment of aggregation-mediated disorders
TW200804593A (en) * 2006-01-24 2008-01-16 Domantis Ltd Fusion proteins that contain natural junctions
CA2644405A1 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
WO2008028977A2 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
CA2667466A1 (en) 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
AU2007331672A1 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
US20100166734A1 (en) 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
AU2007337983A1 (en) 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (CCL2, CCL3, CCL5, CXCL11, CXCL12) single-domain antibodies
JP5419709B2 (ja) * 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
EP2121757A2 (en) 2007-02-21 2009-11-25 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
MX2009012650A (es) 2007-05-24 2010-02-18 Ablynx Nv Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
CA2687633A1 (en) 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
US20110053865A1 (en) 2007-11-27 2011-03-03 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
SG185286A1 (en) * 2007-12-13 2012-11-29 Glaxo Group Ltd Compositions for pulmonary delivery
HUE042053T2 (hu) 2008-06-05 2019-06-28 Ablynx Nv Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére
PL2438087T3 (pl) 2009-06-05 2017-10-31 Ablynx Nv Triwalentne konstrukty nanociał przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (hRSV) do zapobiegania i/lub leczenia zakażeń dróg oddechowych
ES2831323T3 (es) 2009-09-03 2021-06-08 Ablynx Nv Formulaciones estables de polipéptidos y usos de las mismas
AU2011214299B2 (en) 2010-02-11 2014-07-31 Ablynx Nv Methods and compositions for the preparation of aerosols

Also Published As

Publication number Publication date
EP3501499B1 (en) 2022-09-07
PT3501499T (pt) 2022-11-22
EP2533761B1 (en) 2019-03-27
EP3501499A1 (en) 2019-06-26
ES2931330T3 (es) 2022-12-28
HRP20191071T1 (hr) 2019-09-20
CA2787718A1 (en) 2011-08-18
US20130019860A1 (en) 2013-01-24
JP7019433B2 (ja) 2022-02-15
US20210346287A1 (en) 2021-11-11
CA2787718C (en) 2018-05-15
US12083219B2 (en) 2024-09-10
HUE044292T2 (hu) 2019-10-28
US20170333344A1 (en) 2017-11-23
JP6283064B2 (ja) 2018-02-21
AU2011214299B2 (en) 2014-07-31
JP2013519654A (ja) 2013-05-30
EP2533761A2 (en) 2012-12-19
WO2011098552A2 (en) 2011-08-18
CY1122634T1 (el) 2021-03-12
JP2018083839A (ja) 2018-05-31
PT2533761T (pt) 2019-06-17
LT2533761T (lt) 2019-07-10
US9713589B2 (en) 2017-07-25
CN105380904A (zh) 2016-03-09
SI2533761T1 (sl) 2019-08-30
US11007146B2 (en) 2021-05-18
ES2738114T3 (es) 2020-01-20
PL3501499T3 (pl) 2023-01-09
DK2533761T3 (da) 2019-06-24
JP5951508B2 (ja) 2016-07-13
PL2533761T3 (pl) 2019-09-30
WO2011098552A3 (en) 2012-03-29
CN102753148B (zh) 2018-01-26
JP2016193923A (ja) 2016-11-17
CN102753148A (zh) 2012-10-24
AU2011214299A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
IL263729A (en) Preparations and methods for removing biofilms
HK1222128A1 (zh) 用於製備氣霧劑的方法和組合物
HK1185796A1 (zh) 包含近端支化化合物的組合物及其製備方法
HK1202071A1 (zh) 殺生物劑組成物及其使用方法
EP2536756A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
ZA201402734B (en) Collector compositions and methods of using the same
EP2584897A4 (en) COMPOSITIONS CONTAINING RESVERATROL AND METHODS OF USE
EP2569425A4 (en) ENDORIBONUCLEASE COMPOSITIONS AND METHOD FOR THEIR USE
IL222969A0 (en) Sweetener compositions and methods of preparing the same
GB2507210B (en) Insecticidal compositions and methods of using the same
EP2596112A4 (en) ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR
EP2629742A4 (en) HAIR CARE COMPOSITIONS AND RELATED METHODS
EP2582664A4 (en) PHENYL THIOACETATE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
EP2552202A4 (en) METHODS AND COMPOSITIONS FOR WEIGHT LOSS
EP2539444A4 (en) COMPOSITIONS AND METHODS FOR THE PRODUCTION OF L-HOMOALANINE
HK1189501A1 (zh) 抗體組合物及使用方法
EP2633047A4 (en) COMPOSITIONS AND METHOD FOR PRODUCING BLOOD PLATES AND USE METHOD THEREFOR
HK1201451A1 (zh) 組合物及其製備方法
GB201018650D0 (en) Methods and compositions
IL226174A0 (en) Impulse preparations and methods for their preparation
HK1254904B (zh) 用於改變xlhed表型的組合物和方法
GB201020357D0 (en) Compounds and methods of making the same
GB201002278D0 (en) composition and method of preparation
HU1000328D0 (en) Nanostuctured indometachine compositions and process for their preparation
HU1000329D0 (en) Nanostuctured ibuprofene compositions and process for their preparation